RECRUITING

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to assess the safety and efficacy of multiple study interventions including novel-novel combinations or novel agents in combination with standard therapy for the treatment of metastatic NSCLC.

Official Title

A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer

Quick Facts

Study Start:2025-11-24
Study Completion:2029-02-23
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06996782

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. Age 18 years or older
  2. Willing and able to provide informed consent
  3. Able to understand and follow study procedures
  4. Stable medical condition
  1. Pregnancy or breastfeeding
  2. Severe psychiatric disorders
  3. Active substance abuse
  4. Unstable medical conditions
  5. Inability to comply with study requirements

Contacts and Locations

Study Contact

AstraZeneca Clinical Study Information Center
CONTACT
1-877-240-9479
information.center@astrazeneca.com

Study Locations (Sites)

Research Site
Phoenix, Arizona, 85054
United States
Research Site
Santa Rosa, California, 95403
United States
Research Site
Jacksonville, Florida, 32224
United States
Research Site
Baltimore, Maryland, 21201
United States
Research Site
Detroit, Michigan, 48202
United States
Research Site
Rochester, Minnesota, 55905
United States
Research Site
Cleveland, Ohio, 44106
United States
Research Site
Providence, Rhode Island, 02903
United States
Research Site
Tyler, Texas, 75708
United States

Collaborators and Investigators

Sponsor: AstraZeneca

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2025-11-24
Study Completion Date2029-02-23

Study Record Updates

Study Start Date2025-11-24
Study Completion Date2029-02-23

Terms related to this study

Keywords Provided by Researchers

  • Checkpoint inhibitor
  • Platinum-based chemotherapy
  • Interleukin-2 (IL-2)
  • T-cell immunoreceptor with Ig and Immunoreceptor Tyrosine-based Inhibition Motif (ITIM) domains (TIGIT)
  • Programmed death-ligand 1 (PD-L1)

Additional Relevant MeSH Terms

  • Advanced or Metastatic Non-small Cell Lung Cancer